XMXinjian Mao

Xinjian Mao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xinjian Mao has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expansion of functional human long-term HSCs through restraining excessive cell cycle activation

    by Xinjian Mao, Ning Zhang, Xi He, Ruochen Dong, Zhe Yang, Michael Epp, Mark Hembree, Linda Zhang, Yiran Meng, Allison Scott, et al.

    Ex vivo expansion of human hematopoietic stem cells (HSCs) holds promise for overcoming their limited availability, which is a major barrier to their broader clinical application. Although recent advances in culture systems may increase HSC numbers, these conditions frequently impair self-renewal and induce myeloid bias, and the underlying molecular mechanisms remain poorly understood. Here, we performed single-cell multiome sequencing (scMultiome-seq) on human umbilical cord blood-derived CD34+ hematopoietic stem and progenitor cells (HSPCs) to coprofile transcriptional and epigenetic adaptations within the same cells during ex vivo culture. Our analyses revealed reduced transcriptional and epigenetic HSC signatures, accompanied by markedly increased activity of myeloid-associated transcription factor motifs, providing molecular insight into the functional decline and myeloid bias of cultured HSCs. We further observed substantial functional heterogeneity among phenotypically defined HSCs after culture. To address these limitations, we established a niche-mimetic culture system that integrates intrinsic and extrinsic bone marrow regulatory cues, including pharmacologic inhibition of the m6A reader YTHDF2 using the small molecule Y13-27, a 3-dimensional (3D) microenvironment, and N-cadherin-mediated adhesion. This condition (3D-NcadP-Y) robustly preserved long-term repopulating capacity. When combined with the self-renewal agonist UM729, the resulting platform (3D-NcadP-Y-UM) uniquely enabled the expansion of serially transplantable long-term HSCs with balanced multilineage potential. scMultiome-seq and cellular analyses demonstrated that this condition preserves transcriptional and epigenetic long-term HSC signatures, maintains multilineage-associated transcription factor motifs, and limits excessive cell cycle activation. Together, these findings elucidate the molecular mechanisms underlying culture-induced HSC dysfunction and establish a niche-mimetic strategy for expanding functional human long-term HSCs while preserving key features of stemness.


  • Faculty Opinions recommendation of Uncovering the emergence of HSCs in the human fetal bone marrow by single-cell RNA-seq analysis.

    by Linheng Li, Xinjian Mao

    In recent years, single-cell RNA-sequencing (scRNA-seq) has advanced our understanding of human embryonic hematopoietic stem cell (HSC) development in the aorta-gonad-mesonephros (AGM) region and fetal liver, as well as HSC maintenance in adult bone marrow (BM). However, it is still largely unknown the characteristics of human HSCs in fetal BM, as well as the differences between fetal and adult BM. In this manuscript, the Cheng group and collaborators comprehensively deciphered the characteristics of human HSCs and the niche components in fetal BM via performing scRNA-seq on the cells collected from human fetal BM during 10-14 post-conception weeks (PCWs). First, the authors successfully identified and annotated numerous hematopoietic cells, endothelial cells, and stromal cell clusters. Next, transplanting fetal BM hematopoietic cells into immunodeficient mice identified that the functional HSCs first appeared in human fetal BM at 12 PCWs. The authors then systematically characterized the molecular features of HSCs in fetal BM at different stages. They also elucidated the niche cell components in fetal BM and predicted the potential interactions between HSCs and niche cells dynamically from the developmental stages of fetuses to adults. In addition, functional HSCs were not detected in the human fetal spleen before 14 PCWs. Overall, this research characterizes human HSCs and the microenvironment in human fetal BM at different stages, supplementing a missing puzzle of a full single-cell transcriptomic landscape of human fetal HSCs and microenvironment.

  • Faculty Opinions recommendation of EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.

    by Linheng Li, Xinjian Mao

    Chimeric antigen receptor (CAR) T cell-based cancer immunotherapy has shown a great clinical benefit in treating tumor cells. The generation of functional T cells from human pluripotent stem cells (PSCs) in vitro could theoretically provide an unlimited number of T cells for clinical application, but this is currently still unattainable. In this study, the Daley group developed a stroma-free and serum-free T cell differentiation protocol that can induce human PSCs to mature T cells. Knockdown of the histone methyltransferase EZH1 can facilitate this process. The induced T cells show diverse T cell receptor repertoire and molecular signatures like human peripheral blood-derived T cells. In addition, functional evaluation of these T cells was performed rigorously, which assessed their potential to differentiate into effector and memory T cells upon activation, and the anti-tumor capacity of CAR-T cells engineered from PSC-derived T cells. Overall, the article introduced a method for generating functional T cells from human PSCs. Although rigorous evaluation of these PSC-derived CAR-T cells needs to be performed in various animal models, this method has the potential to benefit the current CAR-T immunotherapy in the future by providing an unlimited number of CAR-T cells and shortening the whole procedure of CAR-T cell generation.

  • Faculty Opinions recommendation of Mapping human haematopoietic stem cells from haemogenic endothelium to birth.

    by Linheng Li, Xinjian Mao

    The ontogeny of human hematopoietic stem cells (HSCs) is still poorly understood. In this study, the authors created a single-cell transcriptome atlas of hematopoietic cells and endothelial cells in human embryos at different stages of hematopoietic development. The individual stages of hematopoietic development were then characterized, including hemogenic endothelial cell development, nascent HSC emergence, and HSC maturation. The resulting scorecards for these stages were also plotted. By using these scorecards, the authors compared the human pluripotent stem cell (PSC) derived hemogenic endothelial cells and HSPCs to their counterparts in human embryos and discovered several signaling discrepancies that may account for the functional deficiency of these PSC-induced HSCs. Overall, this article identified landmark genes for all stages of embryonic hematopoiesis. This will provide critical insight into the development of new methods to induce human PSCs to functional HSCs in vitro, a milestone in the hematopoietic regeneration field.

  • Open Access

    Long-Term Clearance of Senescent Cells Prevents the Hematopoietic Stem Cell Aging in Naturally Aged Mice

    by Yonghan He, Jianhui Chang, Dongwen Lv, Ha-Neui Kim, Maria Almeida, Xin Zhang, Xinjian Mao, Xinghui Zhao, Linheng Li, Judith Campisi, et al.

    Senescent cells (SnCs) accumulate with age. Genetic or pharmacological clearance of SnCs delays several age-associated disorders and extends the healthspan of both progeroid and wild-type (WT) mice (Baker DJ et al. Nature, 479: 232, 2011; Baker DJ et al. Nature, 530: 184, 2016). In addition, our previous study showed that transient depletion of SnCs could rejuvenated aged hematopoietic stem cells (HSCs) and muscle stem cells in normally aged mice (Chang J et al. Nat Med, 22:78, 2016). These findings suggest that SnCs play a causative role in aging and certain aging-related pathologies, and that selective clearance of SnCs with a senolytic agent that can selectively kill SnCs can be beneficial in part by rejuvenating aged tissue stem cells. Thus, senolytic drugs are potential novel anti-aging agents. However, SnCs can re-accumulate within a few weeks after depletion in mice, suggesting that long-term and intermittent clearance of SnCs is required to extend healthspan, as shown in previous studies (Baker DJ et al. Nature, 479: 232, 2011; Baker DJ et al. Nature, 530: 184, 2016). It is not known how long-term and intermittent clearance of SnCs affects tissue stem cells such as HSCs because HSCs are mostly quiescent in order to self-renew and prevent exhaustion. We used p16-3MR transgenic mice to evaluate the effect on HSCs of long-term and intermittent clearance of SnCs by ganciclovir (GCV), which selectively kills SnCs in these mice. We treated WT and p16-3MR mice with GCV (25 mg/kg/day x 5 days/per cycle with a 2-week interval between the cycles by ip injection) or saline (vehicle control) from 12 to 24 months of age. GCV effectively prevented SnC accumulation in p16-3MR mice but had no effect in WT mice. In general, aged p16-3MR mice treated with GCV looked healthier than old vehicle-treated p16-3MR mice and old WT mice treated with vehicle or GCV as expected (Baker DJ et al. Nature, 530: 184, 2016). Importantly, GCV abrogated aging-induced increases in p16 expression, p38MAPK activation, and accumulation of DNA double-strand breaks in HSCs in p16-3MR mice. This abrogation was associated with a significant improvement in HSC clonogenicity, suggesting that long-term and intermittent clearance of SnCs prevents HSC aging in naturally aged mice. This suggestion is confirmed by competitive serial and limited dilution HSC transplantation assays, which revealed that HSCs from GCV-treated old p16-3MR mice were functionally indistinguishable from those of young mice. To elucidate the mechanism by which SnC clearance prevents HSC aging, we evaluated the clonogenicity of Lin−Sca1+c-Kit+ (LSK) cells from young or vehicle- or GCV-treated old p16-3MR mice in co-cultures with bone marrow stromal cells (BMSCs) from these mice. We found that clearance of SnCs not only prevented the decline in HSC clonogenic function with aging but also preserved the hematopoietic supporting function of BMSCs. This preservation was associated with reduced levels of Cdkn2a and Cdkn1a mRNAs and senescence-associated secretory phenotype (SASP) factors (such as Il1β, Tnfα and Ccl5), which can adversely affect HSC self-renewal, and decrease of adipogenic and osteoclastic differentiation. In addition, the levels of the HSC self-renewal promoting factor Spp1 mRNA was higher in BMSCs from GCV-treated old p16-3MR mice than in the cells from vehicle-treated old p16-3MR mice. These findings suggest that long-term and intermittent clearance of SnCs can also inhibit BMSC senescence, which contributes to the prevention of HSC aging.